Gastrointestinal Cancer News

Liver resection was safe among patients with metabolic syndrome- and hepatitis C virus-related hepatocellular carcinoma, with only cirrhosis associated with worse short-term outcomes, according to study data.

Transarterial ethanol-lipiodol embolization was a safer and more effective technique for treating patients with hepatocellular carcinoma compared with conventional transarterial chemoembolization, according to study findings.

Advanced spatial analysis identified three areas in the U.S. with excessive death rates from colorectal cancer, according to study results.

Radiation therapy using yttrium-90 resin microspheres combined with chemotherapy did not improve overall progression-free survival in patients with nonresectable metastatic colorectal cancer. However, the combination regimen did improve survival in patients with liver-only metastases, according to newly published data on the SIRFLOX study.

Metastatic colorectal cancer patients with low BMI had shorter overall survival than obese patients, according to a pooled analysis of Avastin studies presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer in Barcelona.

Splanchnic venous thrombosis served as an indicator for occult cancer, according to study results.

The French National Agency for Medicines and Health Products has given Nanobiotix authorization to begin a clinical trial investigating its drug NBTXR3 for the treatment of liver metastasis and hepatocellular carcinoma, according to a press release.

Provectus Biopharmaceuticals, Inc. announced it has signed a Letter of Intent with Boehringer Ingelheim Investment Co. Ltd. in China to collaborate in marketing its potential liver cancer and melanoma drug, PV-10, in mainland China, Hong Kong and Taiwan, according to a press release.

Researchers in Korea used transient elastography and found it to be useful in identifying subclinical cirrhosis among patients at risk for hepatitis B virus infection-related hepatocellular carcinoma who did not have evidence of cirrhosis, according to study data.

The FDA today granted priority review to MM-398 — an irinotecan liposome injection also known as “nal-IRI” — for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine, according to a press release from the drug’s manufacturer.